|
Market Closed -
Nasdaq
01:30:00 03/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 219.72 USD | -4.96% |
|
-14.16% | -44.75% |
| 17/09 | Alnylam Pharmaceuticals, Inc. - Special Call | |
| 14/09 | Alnylam Pharmaceuticals, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 10:00 AM |
| Market Cap | 2.94TCr 2.61TCr 2.44TCr 2.22TCr 4.19TCr 2,82600Cr 4.23TCr 30TCr 11TCr 1,44500Cr 11TCr 11TCr 4,63700Cr | P/E 2026 * |
33x | P/E 2027 * | 23.2x |
|---|---|---|---|---|---|
| Enterprise Value | 2.64TCr 2.34TCr 2.19TCr 1.99TCr 3.76TCr 2,53500Cr 3.79TCr 26TCr 10TCr 1,29600Cr 9.9TCr 9.68TCr 4,15800Cr | EV / Sales 2026 * |
4.81x | EV / Sales 2027 * | 3.54x |
| Free-Float |
99.82% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| ALNY | Delayed | |
CBOE
| ALNY | Real-time | |
|
Tradegate
| DUL | Real-time | |
|
Boerse Muenchen
| DUL | Real-time | |
|
Deutsche Boerse AG
| DUL | Delayed | |
|
Xetra
| DUL | End-of-day quote | |
|
Berne S.E.
| DUL | End-of-day quote | |
|
London S.E.
| 0HD2 | Delayed | |
|
Mexican S.E.
| ALNY * | End-of-day quote | |
|
Börse Stuttgart
| DUL | Delayed | |
|
Borsa Italiana
| 1ALNY | End-of-day quote | |
|
Wiener Boerse
| ALNY | End-of-day quote |
Last Transcript: Alnylam Pharmaceuticals, Inc.
| 1 day | -4.96% | ||
| 1 week | -14.16% | ||
| Current month | -10.95% | ||
| 1 month | -16.93% | ||
| 3 months | -29.75% | ||
| 6 months | -31.09% | ||
| Current year | -44.75% |
| 1 week | 219.4 |  | 257.27 |
| 1 month | 219.4 | | 272.08 |
| Current year | 197.81 | | 427.05 |
| 1 year | 197.81 | | 495.55 |
| 3 years | 141.98 | | 495.55 |
| 5 years | 117.58 | | 495.55 |
| 10 years | 31.38 | | 495.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 01/01/2022 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 58 | 13/08/2019 |
| Chief Tech/Sci/R&D Officer | - | 01/04/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Dennis Ausiello
BRD | Director/Board Member | 80 | 23/04/2012 |
Amy Schulman
CHM | Chairman | 65 | 05/01/2023 |
David Pyott
BRD | Director/Board Member | 72 | 18/12/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 19/09/26 | Free | Chief Executive Officer | 107 | 0.0001% | ||
| 01/06/26 | Exercice | Director | 11,490 | 0.0086% | ||
| 01/06/26 | Free | Director | 4,393 | 0.0033% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.96% | -14.16% | -51.85% | +27.07% | 2.94TCr | |
| -0.61% | -3.43% | +36.07% | +117.61% | 1,01900Cr | |
| -1.02% | -5.60% | +35.72% | +64.82% | 62TCr | |
| +1.11% | -0.58% | +12.36% | +78.27% | 46TCr | |
| +0.34% | -3.01% | +61.79% | +41.79% | 36TCr | |
| -0.95% | -4.05% | +20.54% | +40.33% | 33TCr | |
| -1.46% | -2.89% | +10.57% | +26.54% | 27TCr | |
| -1.35% | -5.43% | -6.17% | +8.82% | 24TCr | |
| -1.04% | -2.79% | +35.30% | +54.42% | 22TCr | |
| -1.87% | -4.10% | +28.44% | +97.54% | 18TCr | |
| Average | -1.18% | -4.47% | +18.28% | +55.72% | 37.27TCr | |
| Weighted average by Cap. | -0.63% | -3.41% | +28.43% | +70.80% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 548.18Cr 487.06Cr 454.59Cr 414.34Cr 781.45Cr 53TCr 788.72Cr 5.5TCr 2.13TCr 27TCr 2.06TCr 2.01TCr 86TCr | 694.44Cr 617.01Cr 575.88Cr 524.9Cr 989.95Cr 67TCr 999.17Cr 6.97TCr 2.7TCr 34TCr 2.61TCr 2.55TCr 1,09500Cr |
| Net income | 90Cr 80Cr 75Cr 68Cr 128.35Cr 8.66TCr 129.55Cr 903.6Cr 350.14Cr 4.42TCr 338.05Cr 330.71Cr 14TCr | 128.61Cr 114.27Cr 106.65Cr 97Cr 183.34Cr 12TCr 185.04Cr 1.29TCr 500.14Cr 6.32TCr 482.86Cr 472.38Cr 20TCr |
| Net Debt | -303.46Cr -269.63Cr -251.65Cr -229.37Cr -432.6Cr -29TCr -436.62Cr -3.05TCr -1.18TCr -15TCr -1.14TCr -1.11TCr -48TCr | -480.5Cr -426.92Cr -398.46Cr -363.19Cr -684.97Cr -46TCr -691.34Cr -4.82TCr -1.87TCr -24TCr -1.8TCr -1.76TCr -76TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/26/02 | $219.72 | -4.96% | 16,61,854 |
| 01/26/01 | $231.18 | -6.31% | 20,17,406 |
| 30/26/30 | $246.74 | -2.89% | 10,44,414 |
| 29/26/29 | $254.07 | -0.51% | 7,87,081 |
| 28/26/28 | $255.36 | -0.23% | 11,47,872 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ALNY Stock
Select your edition
All financial news and data tailored to specific country editions
